NEUROGESX, INC. (DELAWARE) (NGSX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

2215 BRIDGEPOINTE PARKWAY SAN MATEO, CA 94404

NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a synthetic capsaicin-based topical patch to manage pain associated with peripheral neuropathic pain conditions, has completed two pivotal Phase 3 clinical trials in PHN and HIV-DSP. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain.

View SEC Filings from NGSX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NGSX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NGSX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MARTELL RON PRESIDENT AND CEO

  • Officer
25,000 2013-01-01 0

GHIGLIERI STEPHEN F EXEC. V.P., COO & CFO

  • Officer
86,293 2012-12-01 0

PEROUTKA STEPHEN J VICE PRESIDENT AND CMO

  • Officer
18,750 2012-11-09 0

MARKELS MICHAEL SENIOR VP,COMMERCIAL & BUS DEV

  • Officer
69,873 2012-09-01 0

KURTZ NEIL M

  • Director
0 2012-06-07 0

NELSEN ROBERT

  • Director
  • 10% Owner
0 2012-06-07 0

GOODWIN BRADFORD S

  • Director
0 2012-06-07 0

ORWIN JOHN A

  • Director
0 2012-06-07 0

NELSON STEVEN H

  • Director
0 2012-06-07 0

LYONS GARY A

  • Director
0 2012-06-07 0

BIENAIME JEAN JACQUES

  • Director
0 2012-02-07 0

DITONNO ANTHONY A PRESIDENT & CEO

  • Officer
  • Director
107,283 2011-12-12 0

TOBIAS JEFFREY K CMO, EVP RESEARCH & DEVE

  • Officer
4,999 2011-09-16 0

ARKIN MOSHE

M. ARKIN (1999) LTD.

  • 10% Owner
  • ALSO MEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUP
No longer subject to file 2011-08-09 0

BREEN DORON

SPHERA FUNDS MANAGEMENT LTD.

MOR ISRAEL

SENATOR RON

  • MEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUP
No longer subject to file 2011-08-09 0

ARCH VENTURE FUND V LP

ARCH VENTURE PARTNERS V LP

ARCH VENTURE PARTNERS V LLC

CRANDELL KEITH

BYBEE CLINTON

LAZARUS STEVEN

NELSEN ROBERT

  • Director
  • 10% Owner
4,187,777 2011-07-21 0

KAWAHATA RUSSELL T VP, PHARMACEUTICAL SCIENCE

  • Officer
0 2011-02-03 0

RINNE SUSAN P VICE PRESIDENT, REGULATORY

  • Officer
0 2011-02-03 0

BLEY KEITH R SVP, NONCLINICAL R & D

  • Officer
0 2011-02-03 0

ARKIN MOSHE

  • 10% Owner
  • ALSO MEMBER OF 10% OWNER GROUP
2,648,107 2010-09-09 0

SVLSF IV, LLC

SV LIFE SCIENCES FUND IV LP

SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS L P

SV LIFE SCIENCES FUND IV (GP), L.P.

  • 10% Owner
61,324 2010-05-03 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MANAGEMENT CO /NY

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2009-07-13 0

PEACOCK BRUCE

  • Director
0 2009-05-28 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments